TNKS2: A Promising Drug Target and Biomarker for PARP5C-related Encounter

Target Name: TNKS2

NCBI ID: G80351

TNKS2

TNKS2: A Promising Drug Target and Biomarker for PARP5C-related Encounter

Paraphrase:

Paraphrase:

Paraphrase:

PARP5C, or poly (ADP-ribose) polymerase 5C, is an enzyme that plays a crucial role in the repair process of DNA damage. Mutations in the PARP5C gene have been linked to a range of disorders, including DNA repair deficiencies, neurodegenerative diseases, and various cancers. The search for new treatments and biomarkers for these conditions has led to the exploration of the potential drug targets, such as TNKS2.

TNKS2: A Potential Drug Target and Biomarker

TNKS2, or ternary N-acetylated K67, is a protein that is expressed in various tissues and cells, including the brain, spinal cord, and peripheral tissues. It has been shown to interact with the protein PARP5C and can modulate its activity. This interaction between TNKS2 and PARP5C makes it a promising drug target for the treatment of PARP5C-related disorders.

Several studies have demonstrated the potential of TNKS2 as a drug target for PARP5C-related diseases. For instance, experiments have shown that inhibiting the activity of TNKS2 can significantly improve the DNA repair capabilities of cells with PARP5C mutations. This has led to the hypothesis that TNKS2 could be a useful biomarker for tracking the effectiveness of PARP5C inhibitors in these conditions.

Furthermore, TNKS2 has also been shown to play a role in the regulation of cellular processes that are relevant to various diseases, including neurodegenerative disorders. The neuroprotective effects of TNKS2 have been attributed to its ability to modulate the activity of PARP5C, which is involved in the production of reactive oxygen species (ROS) that can cause oxidative stress and contribute to neurodegeneration.

The Potential for TNKS2 as a Biomarker

The use of TNKS2 as a biomarker for PARP5C-related disorders has the potential to revolutionize the field of diagnostic testing and personalized medicine. Since TNKS2 is expressed in various tissues and cells, it could be used as a non-invasive diagnostic biomarker for diseases associated with PARP5C mutations.

For instance, the diagnosis of DNA repair deficiencies, such as those caused by PARP5C mutations, could be confirmed by measuring the levels of TNKS2 in patient tissues. This would allow for earlier detection of these conditions and open the door to targeted therapies.

In addition, the use of TNKS2 as a biomarker could also have implications for personalized medicine. By identifying individuals with specific PARP5C mutations, doctors could recommend targeted therapies that are tailored to their unique genetic makeup. This approach could lead to more effective and efficient treatments, reducing the risk of adverse side effects.

The Potential for TNKS2 as a Drug Target

The potential drug targets for TNKS2 are vast, and its role in the treatment of PARP5C-related disorders is just beginning to be explored. One potential target is the inhibition of TNKS2-PARP5C interactions, which could lead to the reversal of DNA repair deficiencies caused by PARP5C mutations.

Several different approaches could be taken to achieve this goal, including the use of small molecules, antibodies, and gene therapies. These therapies would target TNKS2 andPARP5C to prevent or reverse their interactions, leading to the restoration of normal DNA repair processes.

Another potential target for TNKS2 is the regulation of cellular processes that are relevant to neurodegenerative disorders. The neuroprotective effects of TNKS2 could be attributed to its ability

Protein Name: Tankyrase 2

Functions: Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking (PubMed:11739745, PubMed:11802774, PubMed:19759537, PubMed:21478859, PubMed:23622245, PubMed:25043379). Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation (PubMed:19759537, PubMed:21478859). Also mediates poly-ADP-ribosylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination (PubMed:21478859). Mediates poly-ADP-ribosylation of TERF1, thereby contributing to the regulation of telomere length (PubMed:11739745). Stimulates 26S proteasome activity (PubMed:23622245)

The "TNKS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TNKS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets